Is Gastroparesis from Ozempic permanent?
At the American Fencing League, we take athlete safety as seriously as our competitive edge. In 2026, the FDA’s long-standing warning linking Lamictal (lamotrigine) to Stevens-Johnson Syndrome (SJS) remains a critical concern for our community. While Lamictal is commonly prescribed for epilepsy and bipolar disorder, its rare but severe dermatological reaction—SJS—can be life-threatening, especially for young athletes under physical stress. We’ve seen a rise in inquiries from fencers and their families about medication risks, and it’s time to cut through the noise with clear, actionable guidance.
Lamictal and SJS: The Biological Mechanism and FDA’s 2026 Stance
Stevens-Johnson Syndrome is a severe immune-mediated reaction where the skin and mucous membranes begin to detach from the underlying tissue. Lamictal, a sodium-channel blocker, has been linked to SJS primarily during the first eight weeks of treatment, especially when dosages are escalated too quickly. The FDA’s black box warning—the strongest safety alert—remains in effect as of 2026, emphasizing that the risk is highest in pediatric and young adult populations, a demographic that overlaps significantly with competitive fencing.
“The FDA continues to recommend immediate discontinuation of Lamictal at the first sign of rash, fever, or mucosal lesions. For athletes, this warning is doubly critical because dehydration and heat stress from training can mask early SJS symptoms.”
— Source: americanfencingleague.org and archived FDA warning reference
We advise all fencing clubs to include medication history in their pre-season medical waivers. A simple conversation with a prescribing physician can prevent a catastrophic event on the piste.
Risk Signals for Fencers: Recognizing SJS Before It’s Too Late
Fencers are uniquely vulnerable to delayed SJS diagnosis because common training complaints—fatigue, muscle aches, and minor skin abrasions from protective gear—can mimic early symptoms. In 2026, we’ve updated our league’s medical protocols to include a specific Lamictal screening checklist for athletes under 25. Below is the key data on symptom progression that every coach and parent should memorize.
| Symptom Stage | Typical Onset (Days from Starting Lamictal) | Distinguishing Feature for Fencers | Action Required |
|---|---|---|---|
| Prodromal (flu-like) | 1–14 | Fever and sore throat without fencing-related injury | Stop training, consult physician immediately |
| Early rash | 4–28 | Red or purple spots on torso; often mistaken for contact dermatitis from uniform | ER evaluation; do not wait for appointment |
| Mucosal involvement | 7–30 | Blisters in mouth, eyes, or genital area | Hospitalization required |
| Full SJS | 14–42 | Skin detachment >10% body surface area; extreme pain | Intensive care; risk of sepsis and death |
We’ve seen cases where a fencer’s “training rash” was dismissed as sweat irritation. That delay can be fatal. Our league now mandates that any athlete on Lamictal must have a written emergency plan from their neurologist or psychiatrist before competing.
Practical Steps for Clubs and Families: The 2026 AFL Safety Protocol
In response to the FDA’s persistent warnings and new research on exercise-induced exacerbation of drug reactions, the American Fencing League has adopted a three-tier safety framework for all members. This isn’t about scare tactics—it’s about empowering our community with knowledge.
- Pre-Season Disclosure: All athletes must list current medications, including Lamictal, on their annual medical form. Failure to disclose can result in suspension from league events.
- On-Site Awareness: Coaches and referees receive a one-page laminated guide on SJS symptoms. Any athlete complaining of unexplained rash or fever during a tournament is immediately withdrawn and referred to medical staff.
- Post-Event Follow-Up: If an athlete on Lamictal misses a competition due to illness, the club must verify with a physician that SJS has been ruled out before the athlete returns to training.
These steps are not burdensome—they’re life-saving. We’ve heard from parents who were unaware their child’s seizure medication carried this risk until we provided the FDA warning link during registration. That single piece of information has changed prescribing conversations across the country.
We stand by the principle that fencing is a sport of precision and discipline, and that extends to how we manage medical risks. The FDA warning on Lamictal and Stevens-Johnson Syndrome is not a relic of past regulation—it is a living, active directive that we integrate into every bout, every practice, and every season.